1Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 2Abramson Cancer Center and Abramson Family Cancer Research Institute, University of ...

Radiation Research Program, Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland. *Corresponding Author: Jeffrey C. Buchsbaum, Radiation Research Program, Division of Cancer Treatment ...

This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.

1Department of Microbiology, University of Pennsylvania, Philadelphia, Pennsylvania. 2Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia ...

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...

1Department of Epidemiology and Biostatistics, School of Public Health, Wuhan University, Wuhan, China. 2Department of Gastrointestinal Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China.

1Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas. *Corresponding Author: Guillermina Lozano, Department of Genetics, The University of Texas MD Anderson ...

Clinical cancer research featuring science-based clinical trials is an area of significant growth that aims to determine efficacy and safety of drugs and treatment regimens. In this AACR journals ...

1State Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou, China. 2Institute of Tumor Pharmacology, College of Pharmacy, Jinan University, Guangzhou, China.

1Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China. 2Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University, Fuzhou, China.

A 14-gene molecular assay can help identify patients with lung cancer who could benefit from chemotherapy after surgery, according to results of a study presented at the 2025 American Society of ...

Results from the phase III ASCENT-04/KEYNOTE-D19 study indicate that the combination of sacituzumab govitecan, a TROP2 antibody–drug conjugate, with the PD-1 inhibitor pembrolizumab is superior to ...